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1 Zusammenfassung 
Typ 2 Diabetes mellitus (T2DM) geht einher mit einer Reduktion der Anzahl Betazellen. 
Besonders toxische Oligomere, die bei der Bildung von IAPP-Ablagerungen entstehen, führen 
zu einer Schädigung von Betazellen. 
 
Derzeit zielt keine der heutigen Behandlungsstrategien auf eine Verminderung der 
IAPP-Aggregation ab. Der humane Antikörper NI-203.26C11, der aggregiertes humanes 
IAPP bindet, bewies in vorhergehenden Studien mehrmals seine therapeutische Wirksamkeit 
in transgenen Ratten, die humanes IAPP exprimieren (RIPHAT). Dieses therapeutische 
Wirkprinzip wurde in dieser Studie mit einem zweiten Antikörper (NI-203.11B12) getestet. 
Zusätzlich wurde die therapeutische Wirksamkeit einer Kombinationstherapie mit 
NI-203.26C11 und Metformin evaluiert. 
 
Mit NI-203.11B12 und NI-203.26C11 behandelte RIPHAT Ratten zeigten eine verbesserte 
Glucosetoleranz und eine erhöhte Insulinsekretion im Vergleich zu Kontrolltieren. Metformin 
verbesserte die Glukosetoleranz ebenfalls, jedoch ohne die Insulinsekretion zu verändern. Die 
Kombinationstherapie von Metformin und NI-203.26C11 führte auch zu einer verbesserten 
Insulinsekretion in RIPHAT Ratten. Somit scheint die Antikörpertherapie, wie auch eine 
kombinierte Behandlung, welche einerseits auf einer Verbesserung der Insulinsensitivität 
durch Metformin und andererseits auf dem Schutz von Betazellen durch die Antikörper 
NI-203.26C11 oder NI-203.11B12 beruht, sehr vielversprechend. 
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2 Summary 
Human Type 2 diabetes mellitus (T2DM) is characterized by a reduction in functional 
beta-cells. Especially the toxic oligomers, which are produced during the aggregation of IAPP 
monomers into fibrils and amyloid deposits, damage the beta-cells. 
 
At present, none of the current treatment strategies are aimed at the inhibition of the formation 
of IAPP aggregation. The human antibody NI-203.26C11, targeting aggregated human IAPP, 
showed its therapeutic efficacy in RIPHAT rats which express human IAPP, in previous 
studies. This therapeutic principle was evaluated in the current study with a second human 
antibody, NI-203.11B12. In addition, therapeutic efficacy of a combination therapy of the 
human antibody NI-203.26C11 and metformin was evaluated. 
 
RIPHAT rats treated with NI-203.11B12 and NI-203.26C11 showed improved glucose 
tolerance and increased insulin secretion compared to controls. Glucose tolerance was also 
improved by metformin alone, but the combination with NI-203.26C11 also improved insulin 
secretion. 
  
Thus, antibody therapy against toxic IAPP oligomers as well as a combined treatment based 
on an improvement of insulin sensitivity by metformin and the protection of beta-cells by the 
antibody NI-203.26C11 or NI-203.11B12 seems very promising. 
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3 Introduction 
3.1 Overview 
Human Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder and it is 
characterized by insulin resistance and impaired beta-cell function and mass. The origin of the 
disease is not yet fully understood, but it is thought to be the result of the interplay of genetic 
and epigenetic factors, and lifestyle factors such as obesity and reduced physical activity. 
Metabolic key features are hyperglycemia, an impaired lipid profile, and increased fatty acid 
oxidation. 
1
 
2
 
3
 
 
Similar to T1DM, important long-term consequences of the high glucose levels are micro- 
and macrovascular damage such as atherosclerosis, retinopathy, nephropathy and neuropathy. 
The severe complications in T2DM and the highly increased number of T2DM patients, 
which is probably linked to increased obesity rates, turned the investigation of new treatment 
strategies into a most relevant research field. 
4
 
5
 
 
 
3.2 Insulin resistance and Beta-cell dysfunction 
Physiologically, beta-cells secrete insulin in a biphasic pattern after taking up a normal meal. 
6
 
Insulin resistance, which occurs very early in T2DM development due to various factors such 
as obesity, less physical activity, and high calorie intake, all of which lead to an impaired 
glucose uptake in peripheral tissue such as muscle, liver and fat tissue, increases the demand 
for insulin. Hence, beta-cells try to compensate by releasing more insulin which often leads to 
overt hyperinsulinemia. In the beginning, this compensatory mechanism is still effective for 
most T2DM diabetics, but at a later stage the beta-cell capacity gets exhausted in people with 
a higher risk, the latter being influenced by genetic or environmental factors. 
2
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When present, hyperglycemia itself can induce pro-apoptotic signals such as endoplasmic 
reticulum (ER) stress, mitochondrial dysfunction and thereby lead to beta-cell apoptosis 
which is part of the complex of glucotoxicity. Other features of T2DM are dyslipidemia with 
increased non esterified fatty acids, which may enhance oxidative stress in beta-cells (referred 
to as lipotoxicity), and changes in lipoproteins. These changes include increased low density-
lipoproteins (LDL) and very low density-lipoproteins (VLDL) while high density-lipoprotein 
(HDL) which has been claimed to protect beta-cells, is decreased in T2DM. 
9
 
 
Besides gluco- and lipotoxicity, the formation of islet amyloid, derived of islet amyloid 
polypeptide (IAPP), also contributes to beta-cell loss. Since these IAPP aggregates occur to a 
much larger extent in T2DM patients, T2DM may also be considered a protein misfolding 
disease such as Alzheimer’s, Parkinson’s and Huntington’s diseases, obviously with a 
different peptide moiety that forms the pathological aggregates in pancreatic islets. 
10
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3.3 Pancreatic islet amyloid formation 
Pancreatic islet amyloid can be found in over 90% of T2DM patients, while it was only found 
rarely in older non-diabetic people. 
11
 Physiologically, IAPP, which is derived from an 89-
amino acid (aa) precursor prepro-IAPP, is stored with insulin in the beta-cells. When glucose 
levels rise, insulin and IAPP are co-secreted from the beta-cells in a ratio of 100:1. 
Monomeric IAPP (also called amylin) serves as a satiation hormone and mediates an 
inhibition of gastric emptying, postprandial glucose release, a reduction of food intake, and an 
increase of energy expenditure.
12
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15
 
 
Initially, the pathophysiology of IAPP-derived aggregates was explained by the amyloid 
hypothesis, which suggests that cytotoxicity is caused by mature amyloid. Newer evidence 
indicated that the apoptosis of the beta-cells is probably better explained by the so-called toxic 
oligomer hypothesis. Toxic oligomers which are formed intracellularly during aggregation of 
IAPP molecules into oligomers and fibrils, lead to a decline of the beta-cell mass. It has been 
proposed that amyloid formation depends on a dynamic balance of assembly and disassembly 
between aggregates, which range from mono-, to small and larger oligomers, and insoluble 
amyloid fibrils. Eventually, amyloid deposits may serve as a nucleus for toxic oligomers. 
3
 
16
 
17
 
Findings from Gurlo et al. (2010) suggest that toxic oligomers are formed intracellularly 
through the secretory pathway and escape degradation through damage in the endoplasmatic 
reticulum and cell membranes.
18
 Usually, the IAPP is stabilized by insulin and the pH in the 
secretory granules in the beta-cells. In T2DM, the increased demand of insulin also leads to an 
increased production of IAPP. This causes an overload of the control mechanism of the cell 
such as unfolded protein response (UPR) and autophagy dysregulation. Misfolded IAPP 
oligomers may then damage the cell membrane, the ER, and thereby induce beta-cell 
apoptosis. In addition, these aggregates may cause changes in the mitochondrial membrane 
potential, which leads to development of reactive oxygen species. Indirectly, IAPP oligomers 
can also contribute to inflammation in the pancreas and damage in beta-cells. 
10
 
16
 
  
Besides in humans, pancreatic IAPP deposits have also been observed in nonhuman primates 
and cats. These species are also prone to develop a form of T2DM similar to humans. IAPP is 
highly conserved among different species, except the region from amino acid 20-29. 
Interestingly, rodents, which do not develop T2DM, possess three proline residues within the 
region 20-29, which prevent the formation of amyloid. 
19
 
20
 
21
 
22
 
 
 
3.4 Rodent model 
The progression of T2DM is slow and in people, it usually takes several years to develop the 
entire pathology with all the consequences of the disease. In contrast, rodent models, which 
recapitulate the specific beta-cell pathology, show faster progression of T2DM, and also 
develop long-term consequences within a shorter period of time. 
 
Different rodent models for T2DM exist which possess at least some features of T2DM. 
Because rodent IAPP is not amyloidogenic, transgenic animals which express human IAPP 
(hIAPP) allow studying the pathophysiology and possible treatments against pathological 
amyloid deposits in pancreatic islets, hence which prevent or stimulate the clearance of IAPP. 
23
 
24
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A heterozygous rat model, called HIP rat or RIPHAT rat, which expresses hIAPP driven by a 
rat insulin II promoter, was developed by Butler et al. (2004). This model spontaneously 
develops a form of T2DM between five and 10 months of age which is characterized by the 
occurrence of islet amyloid and increased beta-cell apoptosis. However, homozygous 
RIPHAT rats show an early onset of T2DM without presence of visible islet amyloid, 
probably due to rapid beta-cell destruction. 
25
 
 
 
3.5 Treatment strategies in T2DM 
3.5.1 Immunotherapy 
Based on the importance of IAPP aggregation in the pathogenesis of T2DM, a treatment 
which addresses this feature would be of primordial relevance. In Alzheimer’s, another 
protein-misfolding disease, the formation of misfolded protein amyloid-Beta protein leads to 
damaging effects in the neurons. Currently, one of the most promising strategies to treat 
Alzheimer’s disease is the development of a passive immunotherapy targeting the amyloid-
Beta protein. In T2DM, different research groups showed that the idea of passive 
immunotherapy may also be of therapeutic value. 
26
 
27
 
29 30
 For a more in-depth discussion, see 
paragraph “4.3 Anti-IAPP antibodies”. 
 
 
3.5.2 Non-insulin dependent therapies of T2DM 
3.5.2.1 Introduction of glucose-lowering treatments (excluding insulin) 
Lifestyle modifications, e.g. diet, weight control and physical action, are essential to support 
oral anti-diabetic therapies, but are often not effective alone. The effectiveness of these oral 
therapies is dependent on the remaining insulin secretory capacity of the beta-cells. A large 
number of different glucose-lowering classes are in clinical use, like metformin, 
sulphonylureas (SU), thiazolidinedione (TZDs), dipeptidyl peptidase 4 (DPP-4) inhibitors, 
sodium-glucose-linked cotransporter 2 (SGLT-2) inhibitors, glucagon-like peptide 1 (GLP-1) 
receptor agonists, meglitinides and alpha-glucosidase inhibitors. The guidelines of the 
American Diabetes Association (ADA) (2017) recommend metformin as an initial 
pharmacologic therapy for treating T2DM. This recommendation of the ADA is supported by 
a comparative effectiveness meta-analysis study which showed that metformin generally 
lowers HbA1C levels approximately 0.9-1.1% compared to SU, TZDs, alpha-glucosidase 
inhibitors, and DPP4 inhibitors. Dual- or triple therapies are recommended if glycemic control 
is no longer achieved. An additive glucose-lowering effect was seen when metformin was 
administered with SU, meglitinide, TZDs or alpha-glucosidase inhibitor. A comparative 
effectiveness study showed that in general improved glucose-lowering effects were seen in 
combined treatments. 
30
 
31
 
 
 
3.5.2.2 Pharmacokinetic mechanism of metformin  
Metformin uptake in intestinal cells is presumably primarily regulated by plasma membrane 
monoamine transporter (PMAT, encoded by gene SLC29A4), which is expressed on the 
luminal side of the enterocytes. Beside the transporter PMAT, OCT3 (gene SLC22A3) may 
also transport metformin. On the basolateral side of the intestinal cell, OCT1 (gene SLC22A1) 
may transfer metformin into the intestinal blood vessels. 
Introduction  
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In the body, the hepatic uptake is regulated by the transporter OCT1 (SLC22A1) and probably 
by OCT3 (SLC22A2), which are both located on the basolateral side of the hepatocytes. 
Beside these transporters, metformin is thought to be excreted by multidrug and toxin 
extrusion protein 1 (MATE1, gene SLC47A1). 
 
Metformin is removed from the body by the kidneys. Circulating metformin is taken up in the 
renal epithelial cells by OCT2 transporter, which is located on the basolateral membrane of 
the renal tubules. Metformin is then excreted into the tubular lumen by MATE1 and MATE2, 
which are both located in the apical membrane of the proximal tubule cells. 
 
Some metformin may then be reabsorbed. Reabsorption of metformin may be mediated by 
OCT1 transporters which are expressed on the apical and subapical domain side of both the 
proximal and the distal tubules. Additionally, the transporter PMA, which is located on the 
apical membrane of renal epithelial cells, may reabsorb metformin, too. 
32
 
 
The average half-life of metformin in blood plasma is approximately 4 -9 hours, but was 
increased up to 14 hours in other compartments such as erythrocytes and gastrointestinal tract. 
30 31
 
 
 
3.5.2.3 Pharmacodynamic mechanism of metformin in relation of T2DM treatment 
Metformin accumulates in mitochondria, leading to an inhibition of the complex 1 of the 
respiratory chain and thus to a suppression of the ATP production, respectively an increased 
cellular adenosinmonophosphat : adenosintriphosphat (AMP : ATP) ratio. Gluconeogenesis, 
which is a very energy-intensive process, is subsequently suppressed. Furthermore, the 
administration of metformin also influences other targets in the mitochondria such as the 
inhibition of the mitochondrial glycerophosphate dehydrogenase (mGPD) from the 
glycerophosphate shuttle which also reduces gluconeogenesis. However, this inhibition does 
not contribute to the reduction of glucose.  
 
The increased AMP:ATP ratio leads to an inhibition of the fructose-1,6-phosphase (FBPase) 
which results in a reduced gluconeogenesis. Beside this effect, an increased AMP : ATP ratio 
by metformin can activate the phosphorylation of the AMP-activated protein kinase (AMPK), 
which is a serine/ tyrosine phosphatase, and influences various pathways in glucose and lipid 
metabolism. Interestingly, the enzyme AMPK can not only be activated by an increase in 
AMP : ATP ratio, but also in other ways by metformin. However, AMPK leads to the 
inhibition of the fat synthesis and the increase of the fat oxidation which is mediated by an 
inactivation (direct phosphorylation) of acetyl-CoA carboxylase (ACC). In addition, AMPK 
influences the lipid metabolism by inhibiting the expression of lipogenic genes such as fatty 
acid synthase, S14, SREBP-1C or different others. 
35
 
36
 T2DM patients, who are treated with 
metformin, showed an improved lipid profile e.g. reduced levels of total cholesterol,  LDL 
and triglycerides. 
37
 Another important action of AMPK is the increase in glucose uptake in 
the skeletal muscle by increasing the GLUT4 translocation activity. 
38
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To summarize, metformin treatment leads to an activation of AMPK-dependent and 
independent pathways, and thereby mediates long-term insulin-sensitizing effects. Besides the 
liver, the intestine may also be a target organ of metformin. The uptake of metformin in the 
enterocytes causes an increase in anaerobic glucose metabolism and thereby a reduction of 
glucose uptake. However, it was observed that the exposure of metformin to the duodenum 
leads to suppression of glucose production, which is mediated by the gut-brain-liver axis and 
thereby activates AMPK and GLP-1. 
38 39
  
 
Another known effect of metformin is a loss of bodyweight, which can be explained by a 
reduced food intake but also due to other factors, such as an increased peripheral use, reduced 
rate of carbohydrate uptake in the intestine and an improvement in insulin action. 
39
 
41 42
 
Different studies have shown that metformin can suppress inflammation by improving 
metabolic changes in T2DM such as hyperglycemia, insulin resistance and dyslipidemia. 
Interestingly, metformin also contributes directly to the reduction of inflammation by 
suppression of pro- and inflammatory cytokines or inhibition of NFκB. 42 43 45 
 
Furthermore, it was also discussed in different studies that metformin influences the 
microbiome. One of this studies had shown that metformin support the gut population of 
Akkermansia spp., which is related to a reduction of inflammation in adipose tissue and 
postprandial hyperglycemia. 
45 46
 
 
 
3.6 Preliminary data with anti-IAPP oligomer antibody treatment 
3.6.1 In vitro studies 
The therapeutic efficacy of a passive immunization with a human-derived antibody targeting 
pathologically misfolded hIAPP was tested in vitro and in vivo. Initially, human-derived 
IgG1 antibodies from healthy elderly subjects, which targeted different forms of hIAPP under 
in vitro conditions, were selected and generated. Subsequently, in vitro studies were 
conducted to validate the affinity and selectivity of the antibodies toward hIAPP aggregations. 
The antibody NI-203.26C11 was shown to possess a high selectivity for the pathological 
hIAPP aggregates and no binding to monomeric hIAPP in healthy subjects. In addition, the 
antibody NI-203.26C11 showed a dose-dependent neutralization of the hIAPP in beta-cells 
and stimulation of the uptake of hIAPP by human macrophages. These preliminary studies 
had been conducted in hIAPP expressing, transgenic mice and rats in collaboration with 
Neurimmune AG, Schlieren. 
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3.6.2 In vivo studies 
3.6.2.1 Mouse study 
In the first in vivo study in collaboration with Neurimmune AG, the therapeutic efficacy of the 
selected human-derived antibody was tested in the homozygous mice model expressing 
hIAPP (FVB/N-TG(Ins2IAPP)RHF/SOEL/J). The mice were treated with the antibody NI-
203.26C11-r or PBS over three months. The therapeutic efficacy was assessed by body weight 
gain and glucose tolerance tests during the study, and the hIAPP-derived amyloid load in the 
pancreas at the end of the study. The treatment showed no improvement in glycemic control, 
glucose tolerance, and no deceleration of the progression in this animal model. However, the 
antibody was assessed to be well-tolerated in mice and did not cause toxic symptoms or 
immunoreactions. The lack of therapeutic efficacy might be explained by the use of an 
inappropriate animal model, indeed the progression of amyloid formation developed very 
rapidly so that the time window for therapeutic intervention may have been too short in this 
diabetic mice model. 
48
 
 
 
3.6.2.2 Rat study I 
The therapeutic efficacy of a chimeric version of the antibody (NI-203.26C11-r), which 
possesses human variable domains and rat igG2B constant regions to reduce antigenicity in 
rats, was tested in male hemizygous RIPHAT rats.  
The antibody NI-203.26C11-r or PBS were administered weekly in male RIPHAT and wild 
type Sprague Dawley rats from the age of 12 weeks over the duration of 18 weeks. The 
therapeutic efficacy was assessed by oral glucose tolerance tests (oGTTs), which were 
performed one week before, as well as 8 and 12 weeks after treatment start. In addition, the 
fasting glucose was measured 4 and 12 weeks after treatment start. At the end of the 
treatment, the rats were sacrificed and pancreatic beta-cell area and islet amyloid was 
evaluated by immunohistochemistry. The glucose tolerance in the treated groups was 
significantly improved compared to the control group. In addition, insulin levels tended to be 
higher and hIAPP levels were significantly increased in the treated RIPHAT-groups compared 
to the control RIPHAT-groups.  However, there were no beneficial effects on body weight, 
fasting blood glucose, or on mean islet and insulin beta-cell area. 
49
 
 
 
3.6.2.3 Rat study II 
A second rat study, with prolonged treatment duration of 28 weeks, was performed in 
RIPHAT and wild type rats with antibody treatment starting at the age of 12 weeks. The rats 
received the NI-203.26C11-r, and isotype control IgG or PBS intraperitoneal injections 
weekly. As before, oGTT were performed monthly. After 28 weeks of treatment, improved 
glucose tolerance, reduced fasting glucose and normalized body weight gain were observed in 
RIPHAT rats treated with NI-203.26C11-r compared to the PBS control group. After 20 
weeks of treatment, a hyperglycemic clamp  was conducted, which showed significantly 
improved insulin secretion in RIPHAT rats  treated with NI-203.26C11-r  compared to 
RIPHAT rats treated with IgG. 
50
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3.6.2.4 Rat study III 
A dose response study with three different doses of the antibody NI-203.26C11-r and a 
control PBS-group was performed in RIPHAT rats and wildtype Sprague Dawley rats. The 
rats received 1 mg/kg, 3 mg/kg or 10 mg/kg, respectively, of the NI-203.26C11-r antibody 
weekly from the age of 12 weeks for a treatment period of 41 weeks. For the assessment of 
the therapeutic efficacy of the different dosages, body weight (BW) was measured weekly and 
oGTTs were performed monthly. The BW gain of the antibody-treated groups was 
significantly increased compared to PBS-treated group starting at 37 weeks of treatment until 
the end of the study; in other words, the BW gain of the 1 mg/kg group showed a significant 
increase compared to the PBS-treated group.  
The glucose tolerance was improved in all antibody treated RIPHAT rats, but especially in the 
1 mg/kg and 10 mg/kg antibody NI-203.26C11 group. At the end of the treatment, fasting 
glucose was significantly decreased in the RIPHAT rats receiving the antibody at a dose of 1 
mg/kg or 10 mg/kg, but not at 3 mg/kg.  
The analysis of the area under the curve (AUC) of insulin during the oGTT indicated that in 
RIPHAT rats, which received the antibody, the insulin curve was improved compared to the 
RIPHAT rats without treatment. In addition, fasting insulin levels tended to be increased in 
the antibody-treated groups compared to the PBS-group. However, no significant differences 
were observed in glucose tolerance, fasting glucose, AUC of insulin or fasting insulin 
between the different doses of the antibody NI-203.26C11. 
 
At the end of the study, the animals were sacrificed and pancreatic islet area and beta-cell 
mass were assessed. Increased pancreatic islet and beta-cell area was observed in the 
antibody-treated groups. The clearance of pancreatic hIAPP aggregates paralleled by 
increased islet macrophage infiltration was observed by the immunohistochemical analysis of 
the pancreas. Hence, the treatment with the antibody NI-203.26C11 showed its therapeutic 
efficacy at different doses, with generally the 1 and 10 mg/kg doses being more efficient than 
the 3 mg/kg dose. 
51
 
 
 
3.7 Current study 
In the current study, an additional human-derived antibody, NI-203.11B12, was tested. The 
goal was to evaluate NI-203.11B12 as a backup antibody to confirm that targeting IAPP 
aggregates is of therapeutic value. For more information about the anti-IAPP antibodies, see 
paragraph “4.3 Anti-IAPP antibodies”.  
 
The second aim of the study was the evaluation of the therapeutic efficacy of a combination 
therapy of the human-derived antibody NI-203.26C11 and metformin. The antibody 
NI203.26C11, which targets toxic IAPP aggregates, proved already its therapeutic efficacy as 
a monotherapy in previous rodent studies. On the other hand, metformin, a frequently used 
first-line glucose-lowering drug, is very helpful in the beginning of T2DM treatment. 
Disadvantageous is that metformin does not exert a direct effect on the protection of beta-
cells. Matveyenko et al. (2009) described that in RIPHAT rats treated with metformin, no 
preservation of the beta-cell content was observed. 
52
 
 
This lead to us to the hypothesis that a combined treatment, which targets the increase of the 
insulin sensitivity by metformin, and the protection of beta-cells by the antibody NI-
203.26C11, may be a promising therapeutic approach in T2DM treatment.  
Material and Methods  
14 
4 Material and Methods 
4.1 Animals and housing conditions 
The study was conducted with 78 hemizygous transgenic male RIPHAT rats (Crl:CD (SD)-Tg 
(Ins2-IAPP) 1Pfi) and 10 wild type male Sprague Dawley rats (WT; Cr:CD (SD)); (Charles 
River Laboratories, Wilmington, MA, USA). Rats were kept in a temperature controlled room 
(21 ±1°C) on a 12:12 hour light/dark cycle (light phase from 2am to 2pm) with ad libitum 
access to standard chow (Extrudate 3436, KLIBA NAFAG, Kaiseraugst, Switzerland) and 
water. Rats were housed in standard cages (Type 2000P, 612x435x216) in groups of two or 
three animals per cage. Before starting any treatment, rats (six weeks old) were handled three 
times per week and given an adaption period of eight weeks before being randomized into 
treatment groups. The experiments were approved by the Veterinary Office of the Canton 
Zurich, Switzerland (authorization number 143/2015). 
 
 
4.2 Study design 
4.2.1 Injection protocol 
At 13 weeks of age, before starting any treatment, a first oGTT was performed and the 
collected data served as a baseline (see paragraph ”4.5 Oral glucose tolerance test (oGTT)” 
for details). After the oGTT, groups were matched for rats’ average fasting glucose, glucose 
tolerance and body weight (BW). The RIPHAT and wildtype (WT) rats received a 
combination of intraperitoneal (i.p.) injections and medicated water treatments, which started 
at 13 and 14 weeks of age, corresponding to week 0 and week 1 of the study, respectively. 
The i.p. treatment was repeated weekly while medicated water was replenished twice weekly. 
BW was measured to monitor the rats’ health and to determine the volume of the i.p. 
injection. 
 
The animals were allocated into different treatment groups: n1 corresponds to the initial 
number of animals, while n2 corresponds to the number of animals after complete exclusion or 
inclusion, which had to be performed due to several reasons (see ‘4.2.2 Excluded animals’). 
 
All WT (n1= 10, n2=11) rats received non-medicated water and were injected i.p. with 
phosphate buffered saline (WT-H2O+PBS; PBS, 1.5 ml/kg, Gibco, Auckland, NZ). RIPHAT 
rats (n1=78, n2=64) were randomly allocated into three i.p. treatment groups. The i.p. 
treatments were: PBS, 1.5 ml/kg (RIPHAT- PBS; Gibco, Auckland, NZ; n1=31, n2=28), a rat 
chimeric version of the human anti-hIAPP antibody NI-203.26C11-r (RIPHAT-26C11; 1.5 
ml/kg (3 mg/kg) BW; n1=31, n2=22) and a rat chimeric version of a different human anti-
hIAPP antibody, the NI-203.11B12-r (RIPHAT-11B12, 1.5 ml/kg (3 mg/kg) BW; n1=16, 
n2=13).  
 
In combination with the i.p. treatment, n2=14 (n1=15) of the RIPHAT-PBS and n2=12 (n1=15) 
of the RIPHAT-26C11 rats received water with added metformin (RIPHAT-MET+PBS and 
RIPHAT-MET+26C11, respectively). Based on this allocation, there were n2=37 (n1=48) 
RIPHAT rats which received water (RIPHAT-H2O) and n2=26 (n1=30) RIPHAT rats which 
received a Metformin solution (RIPHAT-MET; see table 1 and 2 for details and doses).  
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After 28 weeks of the study, a washout was performed; the treatment of the RIPHAT-
MET+PBS and RIPHAT-MET+26C11 groups was stopped. The metformin administration 
was replaced with plain drinking water and the i.p. injections were replaced or continued with 
PBS injections in the RIPHAT-MET+PBS and RIPHAT-MET+26C11 groups. The treatment 
of the RIPHAT-H2O group was conducted for 35 weeks until the end of the study. At the age 
of 48 weeks, all animals were sacrificed. 
 
4.2.2 Excluded animals 
Seven animals were partially excluded (npartially excluded) because of health problems during the 
experiment. Because the health problems could not be directly related to the treatments 
received, their glucose and insulin values were included in the statistics until the time of their 
exclusion. In detail, one rat of the RIPHAT-H2O+PBS group had to be euthanized after 34 
weeks of treatment because of skin reactions at the injection site. In the RIPHAT-
H2O+26C11 group, one rat died due to an obstruction of the lower urinary tract after 21 
weeks of treatment and another one was found dead by an unknown cause 34 weeks after the 
start of the treatment. In the RIPHAT-H2O+11B12 group, two animals had to be euthanized 
after 10 and 32 weeks respectively due to a tumor, likely a lipoma which is not uncommon in 
older rats. Another rat of the RIPHAT-H2O+11B12 group developed peritonitis due to an 
injury by i.p. injection after 11 weeks. In the RIPHAT-MET+26C11 group, one rat died 
because of a lymphoma after 16 weeks of treatment. 
 
At the end of the treatment seven rats had to be completely excluded from the experiment 
(nexcluded=n1-n2-–npartially excluded) and one was newly allocated. Five RIPHAT rats (4 RIPHAT-
H2O+26C11, 1 RIPHAT-MET+26C11) showed very low antibody titers and three RIPHAT 
rats were not correctly genotyped by the animal supplier (1 RIPHAT-MET+PBS, 1 RIPHAT-
MET+26C11, RIPHAT-H2O). The incorrectly genotyped rat of the RIPHAT-H2O+PBS 
group was newly allocated in the WT-H2O+PBS group (n1=10, n2=11). 
 
 
Groups 
i.p. injection  
(1.5 ml/kg) 
Drinking 
water n1 n2 
npartially 
excluded 
WT-H2O+PBS PBS water 10 11 0 
RIPHAT-H2O+PBS PBS water 16 14 1 
RIPHAT-H2O+26C11 NI-203.26C11-r water 16 10 2 
RIPHAT-H2O+11B12 NI-203.11B12-r water 16 13 3 
RIPHAT-MET+PBS PBS metformin 15 14 0 
RIPHAT-MET+26C11 NI-203.26C11-r metformin 15 12 1 
 
Table 1: The allocation in the different treatment groups were based on i.p. injection, plain water or water 
medicated with metformin. n1 corresponds to the initial number of animal, n2 corresponds to the number of 
animals at the end of the study, while npartially excluded corresponds to animals, which were excluded at some time 
point after the beginning of the study.  
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4.3 Anti-IAPP antibodies 
Antibodies were generated as described by L. Hugentobler (2017). Briefly, B cells from 
elderly, healthy humans were screened for antibodies which bound selectively to aggregated 
IAPP without binding to non-aggregated IAPP. During the screening for antibodies targeting 
aggregated IAPP, two antibodies with different amino acid sequences were identified, cloned 
and recombinantly produced in Chinese Hamster Ovary (CHO) cells. Upon production, the 
antibodies were characterized for their selectivity to aggregated IAPP in human diabetic and 
non-diabetic tissue by ELISA, by bio-layer interferometry and by immunohistochemistry. 
 
The antibodies NI-203.26C11-r and NI-203.11B12-r were shown to bind to an overlapping 
conformational epitope by an epitope mapping analysis. Rat chimeric versions of these two 
antibodies were generated for the in vivo studies in rats in order to avoid an anti-human 
immune response. The rat chimeric antibodies are composed of IgG2b of a rat backbone and a 
human variable region. 
 
L. Hugentobler (2017) described the assessment of the affinity and selectivity of 
NI-203.26C11 by using fluorescent and bright field images (See figure 1). 
47 48
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: The assessment of the affinity and selectivity of NI-203.26C11: Fluorescent staining: The presence 
of amyloid (Thio-S)-positive pancreatic islets was confirmed in fluorescent images in RIPHAT but not in WT 
rats. Bright field images of the same pancreatic islets of RIPHAT and WT rats were stained with NI-203.26C11 
and mouse anti-IAPP antibody. NI-203.26C11 staining was observed on amyloid (Thio-S)-positive islets from 
RIPHAT rats  binding to aggregated hIAPP, but without binding to physiological rat IAPP (rIAPP) visualized by 
the mouse monoclonal anti-IAPP antibody on WT rat islets. Interestingly, binding of NI-203.26C11 antibody 
was also seen on Thio-S-negative areas in amyloid (Thio-S)-positive islets from RIPHAT but not WT rats 
(Description from L. Hugentobler (2017), Images from Neurimmune AG, Schlieren). 
49 50
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4.4 Metformin 
Metformin solution was replenished twice weekly by dissolving metformin 
(1,1-Dimethylbiguanide hydrochlorid Metformin, Sigma-Aldrich, Switzerland) in water. The 
administration of metformin was started after one week of the study (14 weeks of age) and 
lasted 28 weeks. The target dose of metformin was 200 mg/kg BW and the concentration of 
metformin (met conc; g/l) was, therefore, adjusted weekly between 3 to 3.8 g/l in drinking 
water. To let the animals adapt to metformin, the metformin concentration in the first two 
weeks of the study was 3 g/l and then increased to a maximum of 3.8 g/l (see table 2 and 
figure 2 for details).  
 
The average water intake (avg WI, ml/kg) over two consecutive days was determined for the 
RIPHAT-H2O group, the RIPHAT-MET and WT-H2O group with the following formula: 
 
𝒂𝒗𝒈 𝑾𝑰 =
𝒘𝒍𝑑𝑎𝑦0 − 𝒘𝒍𝑑𝑎𝑦2 − 𝒍
𝒘 + 
𝒘𝒍𝑑𝑎𝑦1 − 𝒘𝒍𝑑𝑎𝑦2 − 𝒍
𝒘
2
 
 
The water content of the bottles (wl; ml) was measured over two consecutive days (day 0, 
day 1, day 2) and the difference described the water intake over 24 hours. For comparison, the 
difference of the water intake absorption was divided by the weight of the rats in a cage 
(w; kg). The water leakage (l; ml) describes the water loss by removing the bottles and was 
measured before the start of the study and was deducted during measurement. 
 
To determine the average administered metformin dose (avg met dose; mg/kg BW) the 
following formula was used: 
 
𝒂𝒗𝒈 𝒎𝒆𝒕 𝒅𝒐𝒔𝒆 = 𝒎𝒆𝒕 𝒄𝒐𝒏𝒄 ∗ 𝒂𝒗𝒈 𝑾𝑰 
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Table 2: The average dose of metformin corresponding to the weeks of the study, metformin concentration 
(met conc), the average water intake (avg WI) of the treatment groups RIPHAT-MET, RIPHAT-H2O and 
WT-H2O groups.  
  
 average water intake (ml/kg BW/per cage/day) 
weeks 
of the 
study 
met conc 
(g/l) 
avg met 
dose 
(mg/kg/day) 
RIPHAT-MET RIPHAT-H2O  WT-H2O               
1 3 181 60.29 80.21 76.36 
2 3 173 57.77 77.48 78.57 
3 3.5 236 67.29 82.67 84.07 
4 3.5         
5 3.5 244 69.81 78.48 81.08 
6 3.4 230 67.63 78.23 81.08 
7 3.5 230 65.73 78.23 77.34 
8 3.5 213 60.95 81.76 81.43 
9 3.5         
10 3.5 201 57.52 68.86 67.44 
11 3.5 223 63.72 77.33 67.98 
12 3.5 194 55.34 66.93 65.48 
13 3.5         
14 3.5 185 52.81 62.39 60.78 
15 3.8 202 53.16 62.69 58.37 
16 3.5         
17 3.5 207 59.24 62.64 57.45 
18 3.5 204 58.23 65.30 63.89 
19 3.5 205 58.61 67.81 67.45 
20 3.5 180 51.48 68.24 67.45 
21 3.5         
22 3.5 186 53.24 68.58 57.88 
23 3.5 165 47.26 71.19 52.40 
24 3.5 172 49.03 79.40 53.08 
25 3.5 178 50.91 85.27 53.05 
26 3.5         
27 3.5 161 46.09 89.60 49.65 
28 3.5 173 49.46 96.45 48.85 
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Figure 2: The administered average dose of metformin in the RIPHAT-MET groups over the course of the 
study. The lower dashed line corresponds to 200 mg/kg/day; the target dose. The upper dashed line corresponds 
to the upper dose limit of 250 mg/kg/day.  
 
 
4.5 Oral glucose tolerance test (oGTT) 
The first oGTT was performed before the beginning of the study, at 13 weeks of age. The 
following oGTTs were performed 4, 9, 13, 16, 21, 26, 30 and 34 weeks after the onset of the 
study. 
Additionally, non-fasting glucose and insulin levels were measured at 18 weeks of treatment 
(5 hours into the light phase). Fasting glucose and insulin levels were measured after 12 hours 
fasting, 28 weeks after the beginning of the study.  
 
Oral glucose tolerance tests were conducted as described in the dissertation of L. Hugentobler 
in 2017. 
51
 Following a 12 hour fast (from 7pm until 7am), BW was measured and rats 
received a 2 g/kg glucose solution (4 ml/kg BW of 50% glucose, B.Braun, Melsungen, 
Germany) by oral gavage. Rats were briefly anesthetized with isoflurane (3-4%, Attane, 
Piramal Enterprises Limited, Mumbai, India) and blood samples (250 μl full blood/500 μl 
EDTA Microtainer K2E tube, Becton Dickinson, Franklin Lakes, USA) were collected by 
sublingual sampling before (0 min) and 15, 30, 60 and 240 min after the glucose load. Blood 
glucose was measured using a Contour XT glucometer and glucose stripes (Contour, Bayer, 
Basel, Switzerland). 
 
 
4.6 Plasma sampling and analysis 
Plasma sampling was performed as described by L. Hugentobler (2017). The plasma insulin 
concentration was measured using a rat Insulin ELISA kit from Mercodia (Uppsala, Sweden) 
following the manufacturer’s instructions.  
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4.7 Pancreas sampling 
At the end of the study, the pancreas of the rats were collected as described by L. Hugentobler 
(2017). The rats were anesthetized with pentobarbital (60mg/kg, i.p.) and sacrificed by 
exsanguination via the V. cava caudalis at 48 weeks of age. At least 5 ml whole blood was 
collected and plasma was stored at -80°C. The pancreas was fixed in a 4% paraformaldehyde 
(PFA) solution for 24 hours at 4° C, then dehydrated in Shandon Citadell 2000 (Thermo 
Fischer Scientific, Waltham, USA) overnight. This was followed by embedding the pancreatic 
tissue in paraffin blocks (Leica EG1160, using paraplas from Leica Biosystems, Wetzlar, 
Germany), cut into 2.5 µm slices with a microtome (Leica RM2255, Leica Biosystems, 
Wetzlar, Germany), placed on glass slides and dehydrated overnight at 60°C. 
 
 
4.8 Statistics 
Graph Pad Prism 7 (San Diego, USA) was used for the statistics. For the analysis of fasting 
glucose, fasting insulin, area under curve (AUC) of glucose and insulin levels during oGTTs, 
a one-way analysis of variances (One-way-ANOVA) was used followed by Tukey’s multiple 
comparison test. For the analysis of glucose and insulin values during the oGTTs and for 
bodyweight gain over time, a two-way analysis of variances (Two-way-ANOVA) was 
performed followed by Tukey’s multiple comparisons test. For the analysis of the water 
consumption a one-way ANOVA was performed for each week followed by Bonferroni’ test. 
A p-value < 0.05 indicated statistical significance. All data are presented as mean ± SEM. 
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5 Results 
5.1 Animals 
In the literature, the diabetic phenotype was observed to occur at the age 5 – 10 months. 25 
Similarly, as observed in our previous studies, most of the RIPHAT-H2O+PBS rats of the 
current study developed polydipsia, polyuria and weight loss at the age of 9 months with few 
rats showing hyperglycemia. 
51
   
 
The RIPHAT rats treated with the antibody NI-203.26C11 and NI-203.11B12 and of the 
RIPHAT-MET groups showed less clinical signs of the diabetic phenotype compared to the 
control RIPHAT groups. However, after the washout that was performed at 28 weeks of 
study, the RIPHAT-MET groups started to develop diabetes-related symptoms similarly to the 
control RIPHAT groups. However, the RIPHAT-MET-PBS group showed a trend for a more 
severe progression and developed more severe clinical signs than the RIPHAT-MET+26C11 
group.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: The timeline of the experiment with age in weeks, the corresponding weeks of the study, the 
corresponding weeks of antibody and metformin treatment from the 1
st
 to the 9
th
 oGTT and at sacrifice (sac). 
However, the antibody treatment started in week 0 of the study. The metformin treatment started 1 week after 
start of the study and was stopped after 28 weeks of the study, between the 7
th
 and 8
th
 oGTT (washout). For the 
washout, the metformin treatment was stopped and the i.p. injections with NI.203.26C11 in the RIPHAT-
MET+26C11 group were stopped and continued with PBS injections. At this time-point an additional fasting 
glucose was measured. 
  
number of oGTTs 1
st
 2
nd
 3
rd
 4
th
 5
th
 6
th
 7
th
 wash 
out 
8
th
 9
th
 Sac 
age (weeks) 13 17 22 26 29 34 39 41 43 47 48 
weeks of the study 0 4 9 13 16 21 26 28 30 34 35 
weeks of antibody 
treatment 
1 5 10 14 17 22 27 29 31 35 - 
weeks of metformin 
treatment 
- 4 9 13 16 21 26 28 - - - 
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Legend of used symbols   
  
 
  
 
Legend of symbols used to indicate significant differences by one-way ANOVA excluding WT-
H2O+PBS group 
   
μ RIPHAT-H2O+26C11 vs. RIPHAT-H2O+PBS   
λ RIPHAT-H2O+11B12 vs. RIPHAT-H2O+PBS   
* RIPHAT-MET+PBS vs. RIPHAT-H2O+PBS   
ω RIPHAT-MET+26C11 vs. RIPHAT-H2O+PBS   
ρ RIPHAT-H2O+26C11 vs. RIPHAT-H2O+11B12   
γ RIPHAT-H2O+26C11 vs. RIPHAT-MET+PBS   
α RIPHAT-H2O+26C11 vs. RIPHAT-MET+26C11   
κ RIPHAT-H2O+11B12 vs. RIPHAT-MET+PBS   
τ RIPHAT-H2O+11B12 vs. RIPHAT-MET+26C11   
      
The symbols also indicate the level of significance, e.g.:   
RIPHAT-H2O+26C11 vs RIPHAT-H2O+PBS: μ: p < 0.05, μμ: p < 0.01, μμμ: p < 0.001; μμμμ: p < 0.0001 
 
 
Legend of symbols used to indicate the different treatment groups in figures 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: The legend of symbols used for all graphs of the study. To simplify the graphs in the figures the 
significances were reported when p < 0.05. Only significances between RIPHAT groups were reported in figures 
and tables. 
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5.2 Body weight 
The body weight was measured weekly in all rats during the entire study period. The RIPHAT 
and WT-H2O+PBS groups gained weight from the start until the end of the study. After 24 
weeks of the study the BW gain of the different RIPHAT-H2O groups seemed to reach a 
plateau while the BW gain of the WT-H2O+PBS group increased until the end of the study. 
The BW gain of the RIPHAT-H2O+26C11 and RIPHAT-H2O+11B12 groups did not differ 
significantly compared to the RIPHAT-H2O+PBS group or from each other. 
 
The RIPHAT-MET groups showed a reduced BW gain compared to the RIPHAT-H2O 
groups from the start until 28 weeks of the study. These differences were significant at several 
time-points (see figure 5 and table 3). 
The RIPHAT-MET groups were not significantly different between each other, but the BW 
gain of the RIPHAT-MET+26C11 group tended to be higher compared to the RIPHAT-
MET+PBS groups from the begin until 28 weeks of the metformin treatment. After the 
washout in week 28 of the study, the increase of BW gain in the RIPHAT-MET+26C11 group 
was more pronounced compared to the RIPHAT-MET+PBS. The BW gain of the RIPHAT-
MET+26C11 group increased and, after 29 weeks of the study, it was not significantly 
different compared to the RIPHAT-H2O. The BW gain of the RIPHAT-MET+PBS also 
increased but by far not to the same extent than the BW gain of the RIPHAT-MET+26C11 
group. 
 
To summarize, the rats of the RIPHAT and WT groups gained BW during the course of the 
study but with reduced BW gain in the RIPHAT-MET groups. The BW gain among the 
RIPHAT-H2O groups did not differ during the course of the study. The reduced BW gain 
under the metformin treatment is probably reflecting decreased food intake as observed in 
other studies. 
42
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The BW gain over the course of the study 
 
Figure 5: The body weight gain (BW gain; in % of starting body weight in week 0 set to 100%) of the WT-
H2O+PBS and the different RIPHAT groups from onset of the study until sacrifice. The 1
st
 to the 9
th
 oGTT are 
marked with black grid lines, the washout is marked with a blue grid line, and the sacrifice is marked with a red 
grid line. See figure 4 and table 3 for more details. Only significances between the RIPHAT groups were 
reported.   
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weeks 
of study 
WT-
H2O+ 
PBS 
RIPHAT-
H2O+ 
PBS 
RIPHAT-
H2O+ 
26C11 
RIPHAT-
H2O+ 
11B12 
RIPHAT-
MET+ 
PBS 
RIPHAT-
MET+ 
PBS Significances 
0 100 100 100 100 100 100 ns                     
1 103 103 104 103 101 101 ns 
         
  
2 110 109 110 109 104 104 ns            
3 114 113 114 112 107 107 ns 
         
  
4 115 114 115 113 106 107 ns     
  
     
5 118 117 119 117 109 110 ns 
         
  
6 122 121 121 120 112 113 * ,   γ 
 
     
7 125 124 124 122 114 116 * , 
  
γ 
    
  
8 128 127 127 126 116 119 ** ,   γγ , 
 
κ    
9 127 127 127 125 116 118 ** , 
  
γγ , 
 
κ 
 
  
10 130 130 130 128 118 121 ** , ω , γγ , 
 
κ    
11 132 134 134 132 120 123 *** , ω , γγγ , α , κκ 
 
  
12 135 137 137 134 122 126 *** , ω , γγγ , α , κκ    
13 135 135 137 133 121 125 *** , ω , γγγγ , αα , κκ 
 
  
14 136 138 139 135 123 126 **** , ωω , γγγγ , αα , κκ    
15 139 140 142 138 125 128 **** , ωω , γγγγ , αα , κκ , τ 
16 138 139 141 137 124 127 **** , ωω , γγγγ , αα , κκκ , τ 
17 141 141 144 139 126 129 **** , ωω , γγγγ , ααα , κκκ , τ 
18 144 144 147 142 128 131 **** , ωω , γγγγ , ααα , κκκ , τ 
19 146 145 148 143 130 133 **** , ωω , γγγγ , ααα , κκκ , τ 
20 147 147 150 144 131 134 **** , ωωω , γγγγ , ααα , κκκ , τ 
21 146 145 148 143 129 133 **** , ωω , γγγγ , ααα , κκκ , τ 
22 148 147 151 145 131 135 **** , ωω , γγγγ , ααα , κκκ , τ 
23 151 149 153 147 134 137 **** , ωω , γγγγ , ααα , κκκ , τ 
24 152 151 155 149 135 139 **** , ωω , γγγγ , ααα , κκκ , τ 
25 154 152 156 150 136 140 **** , ωω , γγγγ , ααα , κκκ , τ 
26 153 149 154 148 134 138 **** , ωω , γγγγ , ααα , κκκ   
27 154 150 155 149 135 140 **** , ω , γγγγ , ααα , κκκ   
28 153 148 153 148 134 139 **** , ω , γγγγ , ααα , κκκ   
29 156 152 156 151 138 144 **** , 
  
γγγγ , α , κκ 
 
  
30 155 149 154 148 137 143 **** ,   γγγγ , α , κκ    
31 157 152 155 150 140 147 *** , 
  
γγγ , 
 
κ 
 
  
32 158 152 155 151 141 149 *** ,   γγγ , 
 
κ    
33 160 153 155 151 143 150 ** , 
  
γγ 
     
  
34 162 153 156 152 143 149 ** ,   γγ        
35 160 150 152 149 141 148 ** ,     γγ             
 
Table 3: The body weight gain (BW gain; in % of starting body weight in week 0 set to 100%) of the WT-
H2O+PBS and the RIPHAT groups over the course of the study. See figure 4 for the legend of significances 
between the RIPHAT groups. Only significances between RIPHAT groups were reported. 
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5.3 Fasting glucose 
The fasting blood glucose (FG) levels were measured first in week 0 of the study. No 
significant differences were observed between the RIPHAT and WT groups in the absence of 
any treatment.  
 
After the start of the treatment, the FG of the RIPHAT-H2O+26C11 and RIPHAT-
H2O+11B12 groups were significantly decreased compared to the RIPHAT-H2O+PBS group  
at several time-points during the study (see table 4). No significant differences were observed 
between the RIPHAT-H2O+26C11 and RIPHAT-H2O+11B12 during the entire study. 
 
FG was not significantly different among the RIPHAT-MET groups. However, RIPHAT-
MET groups showed reduced FG compared to the RIPHAT-H2O+PBS at several time-points 
during the course of the study (see figure 6 and table 4).  
 
In summary, the FG of the RIPHAT-H2O+PBS increased steadily over the course of the 
study. The FG of the RIPHAT-H2O+26C11, RIPHAT-H2O+11B12, RIPHAT-MET+PBS 
and RIPHAT-MET+26C11 groups were reduced compared to the RIPHAT-H2O-PBS. There 
was no significant difference observed between the antibody treatments in the RIPHAT rats. 
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27 
weeks 
of 
study 
WT-H2O+PBS 
RIPHAT-
H2O+PBS 
RIPHAT-
H2O+26C11 
RIPHAT-
H2O+11B12 
RIPHAT-
MET+PBS 
RIPHAT-
MET+26C11 
Significances 
0 8.15 ± 0.28 8.70 ± 0.23 8.10 ± 0.20 8.20 ± 0.32 7.59 ± 0.25 7.86 ± 0.25 ns 
4 7.94 ± 0.32 8.48 ± 0.31 8.04 ± 0.21 7.91 ± 0.17 7.71 ± 0.20 7.95 ± 0.20 ns 
9 7.58 ± 0.27 8.92 ± 0.30 7.80 ± 0.22 8.17 ± 0.20 8.01 ± 0.31 8.09 ± 0.19 μ 
13 7.48 ± 0.30 8.25 ± 0.20 7.32 ± 0.16 7.24 ± 0.18 7.21 ± 0.19 7.59 ± 0.17 μμ, λλ, ** 
16 6.84 ± 0.19 8.05 ± 0.23 7.56 ± 0.26 7.46 ± 0.26 7.51 ± 0.21 6.95 ± 0.30 ω 
21 7.02 ± 0.19 8.40 ± 0.24 7.72 ± 0.26 8.03 ± 0.19 7.80 ± 0.22 7.67 ± 0.21 ns 
26 6.87 ± 0.14 8.49 ± 0.34 7.58 ± 0.20 7.64 ± 0.21 7.52 ± 0.19 7.77 ± 0.20 * 
28 7.21 ± 0.18 9.58 ± 1.02 8.06 ± 0.65 7.39 ± 0.31 8.07 ± 0.43 7.68 ± 0.28 ns 
30 7.25 ± 0.21 8.97 ± 0.61 7.62 ± 0.38 7.96 ± 0.24 7.81 ± 0.16 7.97 ± 0.23 ns 
34 6.63 ± 0.13 10.71 ± 1.20 9.02 ± 0.92 8.98 ± 0.64 8.59 ± 0.61 8.28 ± 0.18 ns 
35 10.95 ± 2.18 21.62 ± 2.56 21.16 ± 3.23 17.60 ± 1.84 18.53 ± 2.01 19.13 ± 1.83 ns 
 
Table 4: The fasting glucose (FG) of the WT-H2O+PBS and the RIPHAT groups at different time-points over 
the course of the study. See figure 4 for the legend of significances between the RIPHAT groups. Only 
significances between RIPHAT groups were reported. 
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5.4 Fasting insulin 
The fasting plasma insulin (FI) were measured first in week 0 of the study. The FI of the WT-
H2O+PBS groups was significantly increased compared to the RIPHAT groups before the 
start of the treatment. No significant difference was observed among the RIPHAT groups 
before and after the beginning of the antibody treatment.  
 
The FI of the RIPHAT-H2O+26C11 and RIPHAT-H2O+11B12 tended to be higher 
compared to the FI of the RIPHAT-H2O+PBS over the course of the study. Interestingly, the 
FI of the RIPHAT-H2O+11B12 was significantly increased compared to the RIPHAT-
MET+PBS after 9, 13, 16 and 28 weeks of the study. 
 
The FI of the RIPHAT-MET groups did not differ significantly compared to the RIPHAT-
H2O+PBS group. The FI of the RIPHAT-MET+26C11 tended to be increased compared to 
the FI of the RIPHAT-MET+PBS over the course of the study (see table 5 and figure 6). 
 
To summarize, the FI of the RIPHAT-H2O+26C11, RIPHAT-H2O+11B12 and RIPHAT-
MET+26C11 was increased, while the RIPHAT-MET+PBS was comparable to RIPHAT-
H2O+PBS. 
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weeks of 
study 
WT-
H2O+PBS 
RIPHAT-
H2O+PBS 
RIPHAT-
H2O+26C11 
RIPHAT-
H2O+11B12 
RIPHAT-
MET+PBS 
RIPHAT-
MET+26C11 
Signifi- 
cances 
0 0.67 ± 0.58 0.14 ± 0.02 0.16 ± 0.07 0.18 ± 0.12 0.16 ± 0.06 0.14 ± 0.03 ns 
4 0.24 ± 0.09 0.17 ± 0.04 0.17 ± 0.03 0.18 ± 0.04 0.15 ± 0.02 0.17 ± 0.03 ns 
9 0.18 ± 0.05 0.23 ± 0.12 0.21 ± 0.06 0.31 ± 0.15 0.18 ± 0.05 0.20 ± 0.07 ρ, κκ, τ 
13 0.38 ± 0.39 0.17 ± 0.04 0.19 ± 0.04 0.24 ± 0.11 0.16 ± 0.03 0.21 ± 0.13 κ 
16 0.21 ± 0.07 0.18 ± 0.03 0.21 ± 0.07 0.24 ± 0.10 0.16 ± 0.01 0.18 ± 0.04 λ, κκ, τ 
21 0.30 ± 0.14 0.18 ± 0.04 0.20 ± 0.04 0.20 ± 0.04 0.17 ± 0.03 0.18 ± 0.06 ns 
26 0.32 ± 0.19 0.20 ± 0.05 0.20 ± 0.04 0.21 ± 0.03 0.19 ± 0.03 0.21 ± 0.05 ns 
28 0.47 ± 0.41 0.20 ± 0.04 0.24 ± 0.09 0.25 ± 0.05 0.18 ± 0.05 0.22 ± 0.07 κ 
30 0.20 ± 0.07 0.17 ± 0.04 0.20 ± 0.06 0.20 ± 0.07 0.16 ± 0.04 0.20 ± 0.05 ns 
34 0.20 ± 0.07 0.17 ± 0.05 0.20 ± 0.05 0.17 ± 0.04 0.16 ± 0.05 0.18 ± 0.05 ns 
35 1.42 ± 1.06 0.18 ± 0.04 0.28 ± 0.13 0.21 ± 0.09 0.22 ± 0.11 0.21 ± 0.08 ns 
 
Table 5: The fasting insulin (FI) concentrations of the WT-H2O+PBS and different RIPHAT groups at 
different time-points of during the study. See figure 4 for the legend of significances between the RIPHAT 
groups. Only significances between RIPHAT groups were reported. 
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Fasting glucose Fasting insulin 
  
 
Before start of any treatment – 1st oGTT 
 
Before start of any treatment – 1st oGTT 
 
  
 
After 16 weeks of the study – 5th oGTT 
 
 
After 16 weeks of the study – 5th oGTT 
  
 
After 34 weeks of the study – 9th oGTT 
 
 
After 34 weeks of the study – 9th oGTT 
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Fasting glucose Fasting insulin 
  
 
After 35 weeks of the study – 9th oGTT 
 
 
After 35 weeks of the study – 9th oGTT 
 
Figure 6: The fasting glucose and fasting insulin concentrations of the WT-H2O+PBS and the different 
RIPHAT groups before treatment in week 0 of the study (1
st
 oGTT), after 16 weeks of the study (5
th
 oGTT), after 
34 weeks of the study (9
th
 oGTT) and at sacrifice after 35 weeks of the study. See figure 4, table 4 and 5 for 
more details. Only significances between the RIPHAT groups were reported.  
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5.5 Glucose tolerance 
Before the start of any treatment at the 1
st
 oGTT and throughout the entire study, all RIPHAT 
groups showed an impaired glucose tolerance compared to the WT-H2O+PBS group. The 
baseline glycaemia and the AUC of glucose among the RIPHAT groups did not differ 
significantly before the beginning of the treatment. 
 
However, the progression of glucose intolerance in the RIPHAT-H2O+26C11 and RIPHAT-
H2O+11B12 groups slowed down compared to the RIPHAT-H2O+PBS during the course 
study period. The glucose values and AUC of the RIPHAT-H2O+26C11 and RIPHAT-
H2O+11B12 groups were significantly decreased compared to the RIPHAT-H2O+PBS at 
several time-points. Based on glucose AUC and curves, the RIPHAT-H2O+26C11 and the 
RIPHAT-H2O+11B12 group did not differ significantly from each other. 
 
The glucose tolerance and AUC of the RIPHAT-MET+PBS and RIPHAT-MET+26C11 
improved compared to the RIPHAT-H2O+PBS during the entire study period. No significant 
differences were observed between the AUC of glucose and glucose curves of the RIPHAT-
MET+PBS and the RIPHAT-MET+26C11 groups. Two weeks after the washout, the glucose 
tolerance of RIPHAT-MET groups was comparable to the RIPHAT-H2O+26C11 and 
RIPHAT-H2O+11B12 group (see table 6 and 7, and figure 7 and 8). 
 
To summarize, the glucose tolerance and AUC of the RIPHAT-H2O+26C11 and RIPHAT-
H2O+11B12 groups were improved compared to the RIPHAT-H2O+PBS. The glucose 
tolerance curve and the AUC of the RIPHAT-MET groups were improved compared to the 
RIPHAT-H2O+26C11 and RIPHAT-H2O+11B12 groups. After cessation of the treatment in 
the RIPHAT-MET groups, the glucose tolerance of the RIPHAT-MET group was comparable 
to the RIPHAT-H2O+26C11 and RIPHAT-H2O+11B12 group. 
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oGTT / 
weeks of 
study 
time- 
point 
WT- 
H2O+ 
PBS 
RIPHAT-
H2O+ 
PBS 
RIPHAT-
H2O+ 
26C11 
RIPHAT-
H2O+ 
11B12 
RIPHAT-
MET+ 
 
RIPHAT-
MET+ 
26C11 Significances 
1. oGTT 0 8.1 8.7 8.1 8.2 7.6 7.9 ns 
0 weeks 15 10.4 11.6 11.5 11.1 11.0 10.7 ns  
 
30 10.7 13.0 12.3 11.8 11.9 12.5 ns  
 
60 8.7 11.8 11.4 10.6 11.2 12.6 ns  
 
120 8.5 10.3 9.8 8.9 9.4 9.7 ns  
 
240 8.7 8.6 8.6 8.7 8.2 8.8 ns  
2. oGTT 0 7.9 8.5 8.0 7.9 7.7 8.0 ns  
4 weeks 15 10.3 12.2 11.1 10.4 10.9 10.6 ns  
 
30 10.0 14.0 12.3 11.0 11.2 11.2 λλλ, **, ωω 
 
60 8.4 13.4 11.7 10.3 10.9 10.8 λλλ, **, ωω 
 
120 8.9 11.0 10.0 9.3 9.0 9.1 * 
 
240 8.2 8.6 8.3 8.3 7.7 8.0 ns  
3. oGTT 0 7.6 8.9 7.8 8.2 8.0 8.1 ns  
9 weeks 15 10.7 12.8 12.3 11.7 11.5 11.8 ns  
 
30 10.5 14.9 13.6 12.8 12.0 12.2  *, ωω 
 
60 8.6 14.9 12.9 12.3 11.9 12.0 λ, **, ωω 
 
120 8.7 12.4 10.2 10.1 10.1 9.4 λ, ωω 
 
240 8.7 9.0 8.2 8.6 7.9 8.3 ns  
4. oGTT 0 7.5 8.2 7.3 7.2 7.2 7.6 ns 
13 weeks 15 10.9 14.6 13.4 12.3 12.5 11.9 ω 
 
30 10.2 17.2 15.2 13.8 13.3 13.4 λλ, **, ωωω 
 
60 8.7 18.1 15.3 13.8 13.8 13.5 λλλ, ***, ωωωω 
 
120 8.7 13.9 12.5 11.3 10.8 11.0 *, ω 
 
240 8.2 9.0 8.1 8.4 7.9 8.2 ns 
5. oGTT 0 6.8 8.1 7.6 7.5 7.5 7.0 ns 
16 weeks  15 10.2 15.5 13.6 13.1 12.3 11.8  **, ωω 
 
30 9.9 17.9 14.9 14.2 12.9 12.8 μ, λλ, ****, ωωωω 
 
60 8.1 18.8 16.0 14.9 13.4 12.4 μμ, λλλ, ***, ωωωω, α 
 
120 8.0 14.8 12.5 12.3 10.6 9.8  ***, ωωωω 
 
240 8.0 9.1 8.1 8.6 8.3 7.8 ns 
6. oGTT 0 7.0 8.4 7.7 8.0 7.8 7.7 ns 
21 weeks 15 10.1 15.0 13.4 13.5 12.7 12.4 ns 
 
30 9.3 17.2 15.4 15.3 13.7 14.0 *, ω 
 
60 8.1 18.2 16.5 16.1 14.3 14.1 **, ωω 
 
120 7.8 15.4 13.9 13.2 10.8 10.7 ***, ωωω 
 
240 7.9 11.1 8.6 8.8 8.6 7.7 ωω 
7. oGTT 0 6.9 8.5 7.6 7.6 7.5 7.8 ns 
 26 weeks 15 9.8 16.1 13.5 13.2 12.7 12.4 **, ω 
 
30 9.2 17.9 15.1 15.5 13.4 14.4 *, ω 
 
60 8.3 18.5 15.8 16.2 14.2 15.0 *, ω 
 
120 7.5 16.2 13.5 14.0 12.0 11.7 *, ωω 
  240 7.6 11.9 11.1 9.3 8.7 7.6 ωω 
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8. oGTT 0 7.2 9.0 7.6 8.0 7.8 8.0 ns 
30 weeks 15 10.2 17.2 13.7 13.5 13.4 14.1 ** 
 
30 9.5 19.6 15.0 16.3 14.0 16.3 ns 
 
60 8.2 20.4 17.2 17.4 15.3 17.1 * 
 
120 7.9 17.1 15.9 15.5 13.4 13.7 ns 
 
240 8.0 12.4 11.6 10.7 8.3 8.9 ns 
9. oGTT 0 6.6 10.7 9.0 9.0 8.6 8.3 ns 
34 weeks 15 10.0 19.1 16.2 15.5 15.3 15.0 ns 
 
30 9.2 21.4 18.7 18.2 16.8 17.5 ns 
 
60 8.2 22.1 19.9 19.4 18.0 19.4 ns 
  120 7.5 18.4 17.7 16.1 15.6 15.9 ns 
  240 7.6 13.4 14.1 11.9 11.8 11.3 ns 
 
Table 6: The glucose levels of WT-H2O+PBS and RIPHAT groups during the oGTTs at 0, 15, 30, 60, 120 and 
240 minutes. See figure 4 for the legend of significances between the RIPHAT groups. Only significances 
between RIPHAT groups were reported.  
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weeks of 
study 
WT-
H2O+PBS 
RIPHAT-
H2O+PBS 
RIPHAT-
H2O+26C11 
RIPHAT-
H2O+11B12 
RIPHAT-
MET+PBS 
RIPHAT-
MET+26C11 
Signifi-
cances 
0 2139 ± 136 2502 ± 443 2422 ± 404 2295 ± 316 2328 ± 331 2468 ± 383 ns 
4 2111 ± 131 2669 ± 478 2429 ± 377 2261 ± 372 2239 ± 371 2255 ± 306 ns 
9 2144 ± 181 2921 ± 633 2536 ± 428 2506 ± 456 2415 ± 372 2397 ± 292 ns 
13 2115 ± 141 3272 ± 619 2894 ± 682 2686 ± 548 2611 ± 543 2625 ± 560 ns 
16 1987 ± 141 3421 ± 600 2922 ± 654 2865 ± 659 2586 ± 506 2430 ± 427 *, ω 
21 1956 ± 136 3551 ± 976 3117 ± 800 3053 ± 779 2685 ± 578 2616 ± 373 *, ω 
26 1902 ± 168 3716 ± 1185 3192 ± 1089 3157 ± 785 2786 ± 582 2757 ± 500 **, ωω 
30 1986 ± 111 3962 ± 1297 3504 ± 1346 3455 ± 1015 2971 ± 572 3178 ± 729 ** 
34 1912 ± 157 4304 ± 1470 4064 ± 1614 3743 ± 1235 3594 ± 1057 3655 ± 785 ns 
 
Table 7: The area under curve of glucose of WT-H2O+PBS and different RIPHAT groups at different time-
points over the course of the study. See figure 4 for the legend of significances between the RIPHAT groups. 
Only significances between RIPHAT groups were reported.   
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5.6 Insulin levels 
Plasma insulin values were measured during all oGTTs. The insulin response of the WT-
H2O+PBS group was increased compared to the RIPHAT groups. No significant difference 
was observed among the RIPHAT groups before the start of the treatment, and after 4 weeks 
of treatment.  
 
The insulin response of the RIPHAT-H2O+26C11 and RIPHAT-H2O+11B12 groups tended 
to be improved compared to the RIPHAT-H2O+PBS. The insulin values of RIPHAT-
H2O+11B12 were significantly increased compared to the RIPHAT-H2O+PBS group at 
several time-points (see table 8). 
 
The insulin levels of the RIPHAT-MET+26C11 were improved compared to the RIPHAT-
H2O+PBS group, and comparable to the insulin levels of the RIPHAT-H2O+26C11 and the 
RIPHAT-H2O+11B12 groups. After the washout was performed, the insulin levels of the 
RIPHAT-MET+26C11 seemed still increased compared to the RIPHAT-H2O+PBS group. 
The insulin response of the RIPHAT-MET+PBS group was not ameliorated before and after 
the washout, suggesting that metformin does not improve beta-cell function in RIPHAT rats. 
  
To summarize, the treatment of the RIPHAT-H2O+26C11, RIPHAT-H2O+11B12 and 
RIPHAT-MET+26C11 groups improved the insulin response compared to the treatment of 
the RIPHAT-H2O+PBS group. However, the insulin levels of the RIPHAT-MET+PBS group 
showed no improvement and were comparable to the insulin levels of the RIPHAT-H2O+PBS 
group. 
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oGTT/ 
weeks of 
treatment 
Time-
point 
WT-
H2O+PBS 
RIPHAT
-H2O+ 
PBS 
RIPHAT-
H2O+ 
26C11 
RIPHAT-
H2O+ 
11B12 
RIPHA- 
MET+ 
PBS 
RIPHAT-
MET+ 
26C11 Significances 
1. oGTT 0 0.60 0.14 0.16 0.17 0.16 0.14 ns 
  0 weeks 15 0.43 0.25 0.24 0.25 0.21 0.22 ns 
  30 0.38 0.22 0.22 0.18 0.23 0.22 ns 
  60 0.35 0.28 0.27 0.24 0.24 0.28 ns 
  120 0.27 0.22 0.24 0.20 0.24 0.25 ns 
  240 0.30 0.18 0.22 0.17 0.20 0.26 ns 
2. oGTT 0 0.24 0.17 0.17 0.19 0.15 0.17 ns 
  4 weeks 15 0.49 0.29 0.35 0.34 0.27 0.33 ns 
  30 0.40 0.24 0.28 0.32 0.21 0.25 ns 
  60 0.37 0.27 0.34 0.32 0.25 0.30 ns 
  120 0.31 0.26 0.30 0.33 0.24 0.28 ns 
  240 0.33 0.15 0.16 0.18 0.22 0.16 ns 
3. oGTT 0 0.18 0.23 0.21 0.33 0.18 0.22 ns 
  9 weeks 15 0.77 0.47 0.54 0.75 0.41 0.51 ρ, λλ, κκκ, ω 
  30 0.36 0.25 0.32 0.38 0.21 0.24 ns 
  60 0.44 0.35 0.44 0.48 0.23 0.37 Κ 
  120 0.40 0.31 0.37 0.37 0.26 0.31 ns 
  240 0.49 0.25 0.28 0.36 0.23 0.24 ns 
4. oGTT 0 0.38 0.17 0.19 0.26 0.16 0.21 ns 
13 weeks 15 0.73 0.27 0.28 0.38 0.23 0.29 ns 
  30 0.62 0.24 0.28 0.39 0.18 0.22 κκ, τ 
  60 0.51 0.30 0.39 0.48 0.21 0.25 λ, γγ, α, κκκ, ττ 
  120 0.48 0.43 0.46 0.68 0.30 0.34 λλλ, ρρ, γ, κκκκ, ττττ 
  240 0.53 0.28 0.28 0.36 0.18 0.30 κ 
5. oGTT 0 0.21 0.18 0.21 0.25 0.16 0.18 ns 
 16 weeks 15 0.83 0.31 0.41 0.42 0.34 0.39 ns 
  30 0.45 0.21 0.25 0.34 0.21 0.26 ns 
  60 0.41 0.32 0.33 0.37 0.22 0.34 ns 
  120 0.49 0.33 0.38 0.43 0.27 0.37 ns 
  240 0.50 0.33 0.43 0.38 0.24 0.26 γ, α 
6. oGTT 0 0.30 0.18 0.20 0.20 0.17 0.18 ns 
 21 weeks 15 1.09 0.31 0.38 0.32 0.27 0.34 γ 
  30 0.69 0.26 0.32 0.29 0.24 0.31 ns 
  60 0.53 0.26 0.43 0.33 0.27 0.36 μμ, γγ 
  120 0.54 0.37 0.55 0.40 0.30 0.45 μ, γγγ 
  240 0.61 0.32 0.46 0.36 0.27 0.31 μ, γγ, α 
7. oGTT 0 0.32 0.20 0.20 0.22 0.19 0.21 ns 
 26 weeks 15 1.18 0.22 0.38 0.26 0.24 0.33 μ, γ 
  30 0.68 0.23 0.34 0.32 0.21 0.29 ns 
  60 0.50 0.25 0.34 0.30 0.24 0.33 ns 
  120 0.63 0.32 0.44 0.43 0.27 0.44 γ, τ 
  240 0.61 0.34 0.43 0.33 0.25 0.34 γ 
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8. oGTT 0 0.20 0.17 0.20 0.20 0.16 0.20 ns 
 30 weeks 15 0.69 0.21 0.35 0.28 0.24 0.27 ns 
  30 0.51 0.21 0.30 0.30 0.20 0.26 ns 
  60 0.58 0.21 0.40 0.30 0.22 0.30 μ, γ 
  120 0.51 0.30 0.35 0.33 0.27 0.31 ns 
  240 0.57 0.34 0.52 0.30 0.25 0.30 γγ 
9. oGTT 0 0.20 0.17 0.20 0.17 0.16 0.18 ns 
 34 weeks 15 0.99 0.26 0.29 0.33 0.25 0.30 ns 
  30 0.69 0.21 0.28 0.27 0.18 0.27 ns 
  60 0.58 0.26 0.28 0.26 0.22 0.31 ns 
  120 0.54 0.30 0.42 0.46 0.30 0.40 λ, κ 
  240 0.53 0.37 0.42 0.40 0.33 0.35 ns 
 
Table 8: The insulin levels during the oGTTs of the WT-H2O+PBS and different RIPHAT groups at 0, 15, 30, 
60, 120 and 240 minutes. See figure 4 for the legend of significances between the RIPHAT groups. Only 
significances between RIPHAT groups were reported. 
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Before start of any treatment – 1st oGTT Before start of any treatment – 1st oGTT 
 
 
After 16 weeks of the study – 5th oGTT After 16 weeks of the study – 5th oGTT 
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Glucose curves Insulin values 
  
 
After 34 weeks of the study – 9th oGTT After 34 weeks of the study – 9th oGTT 
 
Figure 7: The glucose curves and insulin levels of the WT-H2O+PBS and the different RIPHAT groups before 
treatment in week 0 of the study (1
st
 oGTT), after 16 weeks of the study (5
th
 oGTT), and after 34 weeks of the 
study (9
th
 oGTT). See figure 4, table 6 and 8 for more details. Only significances between RIPHAT groups were 
reported. 
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The AUC of glucose over the course of the study 
 
 
Figure 8: The AUC of glucose of the WT-H2O+PBS and the different RIPHAT groups at different time-points 
over the course of the study. See table 7 for more details. Only significances between RIPHAT groups are 
reported. 
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6 Discussion 
The key characteristics of T2DM are insulin resistance and decreased beta-cell function, 
which result in an impaired insulin secretion. Various factors like glucotoxicity, lipotoxicity 
and IAPP-derived islet amyloid aggregates contribute to the development of T2DM. 
1 3
 The 
IAPP aggregation can be found in over 90 % of the patients of T2DM and is consequently 
discussed to play an important role in the development and progression of T2DM. In 
particular, the formation of toxic oligomers during intracellular IAPP aggregation is 
considered to lead to damage and loss of beta-cells. 
3 11
 Therefore, the prevention of the beta-
cell loss and improvement of the beta cell function by targeting pancreatic IAPP aggregates is 
a valuable treatment strategy. In previous studies, the human-derived antibody NI-203.26C11, 
targeting toxic hIAPP oligomers, was assessed and proved to be a promising treatment against 
T2DM. 
51
 
 
In the current study, the therapeutic efficacy of a second human-derived antibody, the NI-
203.11B12, targeting toxic hIAPP oligomers was evaluated in RIPHAT-rats. The antibodies 
NI-203.26C11 and NI-203.11B12 demonstrate both high affinity and selectivity towards 
pathological human IAPP aggregates in in vitro studies, despite differences in their amino 
acid sequence. These beneficial properties in vitro suggest that they have the same mechanism 
of action and hence the same treatment effect. Therefore, the therapeutic efficacy of the 
antibody Ni-203.11B12 was assessed and compared to a control group and the human-derived 
antibody NI-203.26C11.  
 
A second goal of the current study was to evaluate the therapeutic efficacy of a combination 
therapy of the human-derived antibody NI-203.26C11 with metformin. Metformin is a first 
line therapy in the treatment of T2DM, which improves insulin sensitivity and hence lowers 
the glucose levels in diabetic patients. Although metformin has manifold beneficial effects, it 
was demonstrated that there is no effect of the preservation of the beta-cell content. 
30
 
52
 
Therefore, we wanted to test the therapeutic efficacy of metformin combined with a human-
derived antibody, which gives additional value by preventing the loss of beta-cells by toxic 
hIAPP oligomers. 
 
For the evaluation of the different treatments, the RIPHAT-rat model was used. This model is 
characterized by an impaired glucose tolerance staring at three months of age and the 
development of a diabetic phenotype between five to ten months of age. The diabetic 
phenotype is mainly caused by defective insulin secretion and not by insulin resistance. In 
particular, the IAPP formation occurring in this model reflects an important aspect of T2DM 
pathogenesis in humans. Beside this, as the T2DM in humans, the progression of diabetes is 
slow in this model. Therefore, it is a suitable model to evaluate the therapeutic efficacy of the 
different treatments, especially of the human-derived antibodies NI-203.26C11 and NI-
203.11B12. 
25
 
 
The antibody NI-203.26C11 had already been evaluated in several studies in RIPHAT rats in 
a collaboration with Neurimmune AG. The treatment with the antibody NI-203.26C11 was 
well tolerated and resulted in improved glucose tolerance, reduced hyperglycemia, enhanced 
plasma insulin values, preserved beta-cell content and normalized BW gain in RIPHAT rats. 
In the previous study, the antibody NI-203.26C11 was tested at the doses 1, 3 and 10 mg/kg 
over the course of 41 weeks. Irrespective of the dose, RIPHAT rats, which received the 
antibody NI-203.26C11, preserved their BW, while RIPHAT rats without treatment started to 
lose BW at the age of 37 weeks. At several time points, the fasting glucose was significantly 
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decreased compared to the RIPHAT-PBS group, while no differences between the different 
doses were observed. Based on glucose curves and AUC of glucose, the progression of 
glucose intolerance was reduced in all treatment groups. Fasting insulin and insulin values 
were improved by the antibody treatment, which may suggest an effect of the antibody in 
protecting beta-cell function. To summarize, the antibody NI-203.26C11 improved well-
being, BW gain, glucose tolerance and insulin values at all three doses. 
49 50
 
 
In the current study, BW gain, fasting glucose, glucose levels, AUC of glucose, fasting insulin 
and the insulin levels were measured to evaluate the therapeutic efficacy of a treatment with 
the antibody NI-203.26C11 compared to the antibody NI-203.11B12, with metformin and 
with a combination treatment with the antibody NI-203.26C11 and metformin.   
 
From the start until the end of the current study, all RIPHAT rats and WT rats showed 
increased BW gain. The BW gain of the RIPHAT-H2O+26C11 and the RIPHAT-
H2O+11B12 increased and reached a plateau after 26 weeks of treatment. No difference was 
observed compared to the control group, which received only PBS injections and water for 
drinking. Hence, these findings about NI-203.26C11 were confirmed in the previous studies. 
In an even longer study period of 41 weeks of treatment, it was observed that the BW gain of 
the RIPHAT rats treated with NI-203.26C11 reached a plateau, too. However, in that study, 
the PBS control rats lost weight during the last 4 weeks of the study. 
51
 A difference in BW 
gain could also be expected if the current study would be prolonged. The RIPHAT rats, which 
received metformin, showed reduced BW gain compared to the other groups. This effect is 
most likely reflecting a reduced food intake which is known under metformin treatment. 
37
 
After 28 weeks of the study, the treatment of the metformin and the i.p. injections in the 
RIPHAT-MET groups was stopped, and continued with PBS i.p. injections and plain water 
for drinking (washout). After this washout, BW gain started to increase in the RIPHAT-MET 
groups. Interestingly, the BW gain of the RIPHAT-MET+26C11 was already higher 
compared to the RIPHAT-PBS+MET before and the washout and remained higher also 
thereafter. At the end of the study, the BW gain of the RIPHAT-MET+26C11 was 
comparable to the RIPHAT-H2O, while the BW gain of the RIPHAT-MET+PBS increased 
only slightly. This leads to the conclusion that the administration of NI-203.26C11, on top of 
metformin administration, has a beneficial effect on the body weight gain compared to 
metformin alone. 
 
As expected, the fasting glucose (FG) levels of the RIPHAT rat model increased compared to 
the WT rats over the course of the study. 
24 50
 All treatments reduced FG in the RIPHAT rats 
compared to the RIPHAT rats without treatment over the course of the study. There was no 
difference in FG observed between the antibody NI-203.26C11 and NI-203.11B12. The effect 
of reduced FG by the antibody NI-203.26C11 was also observed in previous studies. These 
findings support the idea that the treatment with human derived antibodies targeting IAPP 
lead to a reduction in the FG by improving beta cell function. 
49 50
 
52
 
 
The FG of the RIPHAT rats, which were treated with metformin, was reduced compared to 
the control group. This can be explained by the glucose lowering effect of metformin. 
41
 
42
  
After 28 weeks of the study, the treatment in the RIPHAT-MET groups was stopped. Six 
weeks after the washout was performed, fasting glucose was increased in the RIPHAT-MET 
groups and was comparable to the antibody treatments. It seems that the glucose-reducing 
effect is only observed during metformin administration but vanishes once the treatment 
stopped. 
 
Discussion  
44 
As described in the literature, RIPHAT rats show a slightly impaired glucose tolerance 
starting at an age of 12 weeks. 
25
 In the present study, the progression of T2DM was slowed 
down by the antibody treatments, while severe glucose intolerance developed in the RIPHAT 
rats without treatment over the course of the study. The two antibodies NI-203.26C11 and NI-
203.11B12 improved both the glucose tolerance and the AUC of glucose. Between these two 
treatments, no significant difference was observed. The enhancement of glucose tolerance and 
AUC of glucose by the antibody NI-203.26C11 was also observed in previous studies. 
49 50
 In 
the current study, both antibodies slowed down the progression of glucose intolerance, 
thereby confirming that targeting IAPP aggregates is of therapeutic value. 
 
The treatment of metformin alone or combined with the antibody NI-203.26C11 lead to a 
strongly improved glucose tolerance and to a reduced AUC of glucose compared to the 
RIPHAT rats without treatment. The reduced progression of glucose intolerance was observed 
from 4 until 26 weeks of the study. The observed decreased glucose levels are an expected 
effect of metformin during the oGTTs. 
30
 However, six weeks after the washout, the effect of 
metformin was not present anymore. 
 
The fasting insulin (FI) concentrations tended to be increased in the treatment groups which 
received one of the human-derived antibodies, compared to the RIPHAT-H2O+PBS or 
RIPHAT-MET+PBS groups. Interestingly, the FI of the RIPHAT-H2O+11B12 group was 
significantly increased compared to the RIPHAT-MET+PBS group at several time-points 
over the course of the study. Further investigations need to be done to fully understand the 
reasons for this increase. The FI values were increased by both antibodies, NI-203.26C11 and 
NI-203.11B12, confirming the results obtained with the NI-203.26C11antibody in previous 
studies. 
49 50
  
 
The insulin response seems to be enhanced by the therapy with the antibody NI.203.11B12 
and NI.203.26C11 compared to the control group, as already shown previously. The 
histological examination in previous studies showed a prevention of the loss of beta-cells by 
the antibody NI-203.26C11 compared to the control RIPHAT rats. 
49 50
 A similar effect was to 
be expected also in the current study and as results of the treatment with the antibody NI-
203.11B12. However, histological examination is currently ongoing thus no histological data 
are available at this time. 
 
The insulin values of the combination treatment, metformin and NI-203.26C11, were 
increased, while the insulin values of the RIPHAT rats treated with only metformin were 
comparable to the control RIPHAT rats. Thus, no improvement of the insulin values by 
metformin alone during the oGTT were observed. That metformin has no protective effect on 
pancreatic beta cells and consequently no influence on the insulin response had also been 
described by Matveyenko. 
52
 Interestingly, improved insulin values were also shown after the 
administration of the antibody NI-203.26C11 and metformin was stopped in the RIPHAT-
MET+26C11 group (washout). It seems that a prolonged treatment effect can be observed by 
the administration of the antibody NI-203.26C11. The prevention of beta-cell loss, even after 
the administration of metformin and NI.203-26C11 in the RIPHAT-MET groups was stopped, 
is an important advantage in this T2DM therapy.  
 
  
Discussion  
45 
Limitations of the present study are given by the development of T2DM in this rat model. The 
diabetic phenotype is mainly due to a defective insulin secretion, but not to insulin resistance, 
which is also an important factor in T2DM. However, the RIPHAT animal model is the only 
rat diabetes model that mimics the important characteristics of T2DM, which is the formation 
of amyloid deposits in pancreatic islets. Therefore, despite some disadvantages, it is a very 
useful tool to test the different therapies. 
25 52
 
Another limitation of our approach is given due to the metformin administration in the 
drinking water. The metformin intake is dependent on the water amount of the respective rat, 
which does not always have to be directly dependent on body weight. However, other ways of 
application like oral gavage would not be practicable over a long study period. 
 
To summarize, the human-derived antibodies NI-203.26C11 and NI-203.11B12 showed to be 
well-tolerated and proved their therapeutic efficacy by improving fasting glucose, glucose 
tolerance, insulin responses and BW gain in treated RIPHAT rats. The results of the current 
and previous studies support the idea that targeting hIAPP aggregates by antibodies is a very 
promising treatment strategy.  
 
Combination therapies with metformin, a frequently used glucose-lowering drug which 
mainly affects insulin sensitivity, are very useful in the treatment of T2DM. 
31
 In the current 
study, the human-derived antibody NI-203.26C11 on top of metformin improved the fasting 
glucose and the glucose tolerance. Before, but especially after the washout was performed, we 
could observe that the BW gain and insulin values with the combination therapy are improved 
compared to only metformin treatment in RIPHAT rats. It seems that the insulin response, 
which reflects the beta-cell function, was still improved by the combination treatment. This 
combined treatment, which targets two different pathophysiological features of T2DM, could 
be used as a new treatment strategy in the T2DM therapy. 
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